Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ConocoPhillips (COP) vs Invesco Ltd. (IVZ) Price & Performance

ConocoPhillipsTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

ConocoPhillips vs Invesco Ltd. — how do they compare? ConocoPhillips trades at $133.7 (market cap $155.98B), while Invesco Ltd. trades at $30.09 (market cap $13.47B). The key difference: ConocoPhillips is far larger — about 11.6× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.82%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Invesco Ltd. for 77 Days on average.

COPIVZ
Market Cap
$155.98B$13.47B
Volume
4,774,9514,447,526
Sector
EnergyFinancials
52-Week High
$141.22$33.31
52-Week Low
$85.66$22.44
Typical Hold Time
79 Days77 Days
Enterprise Value
$171.58B$23.63B
Dividend Yield
2.59%2.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ConocoPhillips

ConocoPhillips (COP) trades at $134.19, up 3.74% with strong technical momentum and bullish moving averages. The company shows solid fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global announced October 1, 2026. Valuation metrics remain reasonable with P/E of 17.17 and EV/EBITDA of 6.17, while analyst consensus favors Buy ratings (75%) with a $154.75 price target.

Outlook remains positive given robust cash flow generation and strategic LNG expansion, though risks include oil price volatility and geopolitical exposure. The stock offers value with upside potential to analyst targets, but investors should monitor execution on international asset sales and energy market dynamics.

Invesco Ltd.

Invesco (IVZ) trades at $30.09, down 0.95% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $281.70 million for 2025 despite revenue growth to $6.38 billion, with a negative net margin of -0.93%. Recent earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Positive developments include strong operating cash flow of $1.53 billion in 2025 and the expansion of its QQQ ETF suite.

The outlook is cautiously optimistic, supported by a consensus price target of $33.71 and no sell ratings among analysts. Key opportunities lie in continued AUM growth and ETF innovation, but risks include profitability challenges and market volatility. The stock's current price near support at $30.00 suggests limited downside if fundamentals improve with upcoming earnings.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

COP
1% Buy99% Sell
Avg holding period · 79 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About ConocoPhillips

ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.

Read more on COP →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →